Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma

This trial is not currently accepting patients. This trial is expected to begin accepting patients on or around March 2018.

Trial Overview

This is a phase 1, multi-center, single-arm, open-label study evaluating the safety, tolerability, and anti-myeloma activity of ACTR087 (an autologous T cell product) in combination with SEA-BCMA (a monoclonal antibody) in subjects with relapsed or refractory Multiple Myeloma.

What is the phase of this trial?

Phase 1 what does this mean

What type of trial is this?

This is an interventional trial. This type of trial actively treats your myeloma.

What treatments are used in this trial?
Trial Notifications

Sign up for updates when new locations become available for this trial.

How many patients will participate in this trial?

Approximately 30 patients will be enrolled in this study.

Who is sponsoring this trial?

Unum Therapeutics Inc.

SparkCures Trial Identifiers

MM-0904 , NCT03266692 what is this

Trial Connect

SparkCures can help connect you directly with this trial.

(888) 828-2206

Request a Call

Trial Notifications

SparkCures can notify you when new locations become available.

Sign Up Now

Am I Eligible For This Trial?

All clinical trials provide reasons that patients may or may not be able to join called 'eligibility criteria'. The following is a high-level eligibility criteria provided by the sponsor of this trial. Additional eligibility criteria may apply.

Trial Contact Information

Connect with this trial now

Call SparkCures now at (888) 828-2206 and one of our clinical trial specialists will help connect you with the closest trial site. You can also select a trial location below and sign up to have one of our team members contact you.

There are no active locations for this trial.